Stay updated with breaking news from Development Pillars. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Twenty patients with indolent and aggressive R/R B-NHL received evorpacept plus standard rituximab and lenalidomide – Evorpacept plus R2 was well tolerated with a safety profile similar to...
– Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R2”)– Evorpacept plus...
– Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R2”)
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway,
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 -- ALX Oncology Holdings Inc., , a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced...